Discover

HCM
HUTCHMED (China) Limited
11.21
2 x 11.20
2 x 11.23
bid
ask
+
0.03
0.27%
11:54 AM
timesize
Ytd-15.90%
1y-36.60%
11.19
day range
11.41
9.77
52 week range
19.50
Open11.39Prev Close11.18Low11.19High11.41Mkt Cap1.95B
Vol17.41KAvg Vol49.39KEPS2.67P/E4.19Forward P/E12.87
Beta0.24Short Ratio3.14Inst. Own2.57%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning07-3050-d Avg11.28200-d Avg13.761yr Est22.62

HCM News

Hutchmed: Bullish On Their Commercial Prospects And Pipeline Catalysts
seekingalpha.com
Hutchmed: Bullish On Their Commercial Prospects And Pipeline Catalysts

Hutchmed basically combines a growing oncology franchise with late-stage immunology assets and an ea

AI Solution Providers Shift From AI Features to AI-Enabled Execution
gurufocus.com
AI Solution Providers Shift From AI Features to AI-Enabled Execution

[url="]The Hackett Group, Inc.[/url] (NASDAQ: HCKT), an ROI-led AI transformation firm, today releas

benzinga.com
B of A Securities Maintains Buy on HUTCHMED (China), Lowers Price Target to $17

B of A Securities analyst Alec Stranahan maintains HUTCHMED (China) (NASDAQ:HCM) with a Buy and l

HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET Amplification
globenewswire.com
HUTCHMED Announces NMPA Approval for ORPATHYS® for the treatment of Gastric Cancer Patients with MET

First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or ga

HUTCHMED to Announce 2026 Half-Year Financial Results
globenewswire.com
HUTCHMED to Announce 2026 Half-Year Financial Results

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Li

Buy These 3 HCM Software Solution Stocks to Tap Short-Term Potential
zacks.com
Buy These 3 HCM Software Solution Stocks to Tap Short-Term Potential

AI-driven hiring and HR automation are reshaping HCM software, with three companies, namely, PAYC, P

HUTCHMED's Experimental Drug Shows Durable Responses In Advanced Bile Duct Cancer Trial
benzinga.com
HUTCHMED's Experimental Drug Shows Durable Responses In Advanced Bile Duct Cancer Trial

HUTCHMED reported positive Phase 2 data for fanregratinib in advanced ICC as China reviews the drug.

benzinga.com
Reported Earlier, HUTCHMED's Fanregratinib Achieves 42.5% Objective Response Rate In Pivotal Phase I

— Registration-enabling study demonstrated high clinically meaningful objective responses, achieving

Syndio Acquires Embrace.ai
businesswire.com
Syndio Acquires Embrace.ai

SEATTLE--(BUSINESS WIRE)--Syndio, the Decision Intelligence for Pay company, today announced the acq

isolved Introduces Autonomous AI Agents Built to Own HR Outcomes — Brings Unified HCM Platform to Anthropic's Claude Connectors Directory
globenewswire.com
isolved Introduces Autonomous AI Agents Built to Own HR Outcomes — Brings Unified HCM Platform to An

LAS VEGAS, June 16, 2026 (GLOBE NEWSWIRE) -- Connect For Partners -- isolved ® today unveiled the fi

Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
prnewswire.com
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with ED

– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Cons

isolved Honors Top-Performing Partners at Annual Connect for Partners Event
globenewswire.com
isolved Honors Top-Performing Partners at Annual Connect for Partners Event

LAS VEGAS, June 15, 2026 (GLOBE NEWSWIRE) -- Connect for Partners – isolved®, a provider of human ca

isolved Introduces New Strategic Marketplace Partners at Connect 2026, Extending People Cloud™ Capabilities for Employers and Employees
globenewswire.com
isolved Introduces New Strategic Marketplace Partners at Connect 2026, Extending People Cloud™ Capab

LAS VEGAS, June 15, 2026 (GLOBE NEWSWIRE) -- Connect For Partners – isolved, a provider of human cap

Paychex Recognized as a Top WorkTech Company by TIME
globenewswire.com
Paychex Recognized as a Top WorkTech Company by TIME

Paychex named a leading HCM provider to TIME's America's Top WorkTech Companies 2026 List List ident

HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
globenewswire.com
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia

— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile — —Th

U.S. Office of Personnel Management Selects Oracle to Power Federal Workforce Modernization
gurufocus.com
U.S. Office of Personnel Management Selects Oracle to Power Federal Workforce Modernization

U.S. Office of Personnel Management Selects Oracle to Power Federal Workforce Modernization PR Newsw

Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
globenewswire.com
Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM

All Evaluable Patients Achieved Improvements in Multiple Hallmarks of  MYBPC3-Associated HCM Benefit

Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
globenewswire.com
Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adult

SOUTH SAN FRANCISCO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TN

HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
globenewswire.com
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting

HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHM

HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
globenewswire.com
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with

Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2

Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
prnewswire.com
Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combinatio

Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2

Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Suites
globenewswire.com
Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Mana

HiBob recognized as an ISG Vendor of Excellence for its comprehensive Human Capital Management Suite

Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Platforms
globenewswire.com
Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Mana

HiBob recognized as an ISG Vendor of Excellence for its innovative HCM Platform, highlighting its ab

Earnings Scheduled For March 5, 2026
benzinga.com
Earnings Scheduled For March 5, 2026

benzinga.com
Earnings Scheduled For August 7, 2025

benzinga.com
Earnings Scheduled For February 28, 2024

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings a

benzinga.com
Earnings Scheduled For July 31, 2023

Companies Reporting Before The Bell • Immunogen (NASDAQ:IMGN) is estimated to report quarterly loss

benzinga.com
Stocks That Hit 52-Week Lows On Wednesday

  During Wednesday's trading, 517 companies set new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Tuesday

  On Tuesday, 838 companies hit new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Friday

  On Friday, 404 stocks made new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Friday

  On Friday, 1043 companies hit new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Lows On Thursday

  During Thursday, 166 stocks hit new 52-week lows.

benzinga.com
Stocks That Hit 52-Week Highs On Wednesday

    During Wednesday's morning trading, 125 companies set new 52-week highs.

benzinga.com
Stocks That Hit 52-Week Lows On Monday

Stocks That Hit 52-Week Lows On Monday